Olema Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OLMA research report →
Companywww.olema.com
Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
- CEO
- Sean Bohen
- IPO
- 2020
- Employees
- 96
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.22B
- P/E
- -7.75
- P/S
- 0.00
- P/B
- 2.99
- EV/EBITDA
- -5.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.95%
- ROIC
- -41.66%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-162,451,000 · -25.47%
- EPS
- $-1.87 · 15.00%
- Op Income
- $-178,698,000
- FCF YoY
- -40.38%
Performance & Tape
- 52W High
- $36.26
- 52W Low
- $3.89
- 50D MA
- $14.98
- 200D MA
- $16.44
- Beta
- 2.06
- Avg Volume
- 1.50M
Get TickerSpark's AI analysis on OLMA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Raman Prakash | other | 24,150 |
| Apr 28, 26 | Raman Prakash | other | 2,911 |
| Apr 28, 26 | Raman Prakash | other | 0 |
| Mar 3, 26 | Mitchell Shawnte | other | 15,000 |
| Mar 4, 26 | Mitchell Shawnte | other | 25,000 |
| Mar 4, 26 | Mitchell Shawnte | other | 25,000 |
| Mar 3, 26 | Mitchell Shawnte | other | 15,000 |
| Mar 4, 26 | Mitchell Shawnte | sell | 24,767 |
| Mar 3, 26 | Mitchell Shawnte | sell | 15,000 |
| Mar 4, 26 | Mitchell Shawnte | sell | 233 |
Our OLMA Coverage
We haven't published any research on OLMA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OLMA Report →